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Abstract 
Objective: To evaluate maternal cardiovascular effects of nitric oxide (NO) donors in pregnancies 
complicated by fetal growth restriction (FGR)  
Methods: 26 women with a diagnosis of FGR were treated with transdermal patches of NO donors and 
plasma volume expansion. We compared the treated group to a control historical FGR untreated group of 
patients evaluated longitudinally. We obtained haemodynamic indices using UltraSonic Cardiac Output 
Monitor system. 
Results: At enrolment, the two groups were similar in terms of maternal and haemodynamic 
characteristics. In the treated group, we found a significant increase in cardiac output, stroke volume and a 
decrease of systemic vascular resistance after therapy. No significant differences were found after two 
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weeks in the untreated group. At birth the treated group also gave birth to babies with higher birth weight 
centile. 
Conclusions: Despite the observation nature of the data, the combined therapeutic approach of NO donor 
administration and plasma volume expansion in FGR significantly improves maternal hemodynamic 
indices. 
 
Keywords: fetal growth restriction (FGR), UltraSonic Cardiac Output Monitor, nitric oxide (NO) 
donors, maternal hemodynamic, total vascular resistance (TVR) 
 
 
 
 
 
 
 
 
 
Introduction 
Fetal Growth Restriction (FGR) is a condition in which a fetus is unable to achieve its genetically 
determined potential size. It affects about 8% of pregnancies and is associated with an increased 
perinatal mortality and morbidity (1). 
 
Several studies in the literature have investigated the cardiovascular adaptation in pregnancies 
complicated by FGR demonstrating that they are characterized by a reduced expansion of the 
maternal intravascular space, a lack of increase in stroke volume (SV) and cardiac output (CO) in 
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the very early phase of pregnancy (2,3) and a decreased preload compared with normal 
pregnancies. 
Nitric oxide (NO) is an autocrine and paracrine signalling molecule that is synthesized from L-
arginine by a family of calcium–calmodulin-dependent enzymes called nitric oxide synthases 
(NOS). It is released by endothelial cells with a physiological vasodilating effect that increases 
blood flow. Moreover, it induces a decreased responsiveness to vasopressors and inhibition of 
platelet function (4). 
 
NO has an important effect in regulating placental vascular tone and development. (5) In fact, 
during normal pregnancy it appears to play an important role in normal placental development; its 
production occurs in the uteroplacental tissues and is associated with a reduction in vascular 
resistance of the fetoplacental and uterine circulations (6). These important features of NO donors 
in improving uteroplacental perfusion could be a therapeutic strategy in the management of 
pregnancies complicated by FGR.  
 
 
 
Objective 
The aim of the study was to evaluate the maternal cardiovascular effects of NO donors therapy in 
pregnancies complicated by FGR. The remarkable vasodilatory function of NO donors, associated 
with plasma volume expansion, derived by co-administration of oral fluids, may improve 
pregnancy outcome in FGR acting on the maternal systemic vascular resistance (SVR). 
 
Materials and Methods 
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This was a prospective cohort study conducted at the Department of Obstetrics and Gynaecology, 
Policlinico Casilino Hospital, Rome with the collaboration of the Fetal Medicine Unit, St 
George’s Hospital, University of London. 
 
We enrolled 26 pregnancies complicated by FGR, defined as an estimated fetal weight below the 
10th percentile and abnormal umbilical artery (UA) Doppler, over a continuous period of six 
months. The exclusion criteria were: multiple pregnancy; chromosomal abnormalities; preterm 
rupture of membranes; intrauterine infection; undetermined gestational age; history of maternal 
heart disease; tobacco use; pre-existing chronic medical problems. The 26 patients of Group A 
were treated with NO donors (transdermal patches of glycerine trinitrate at a dosage of 5 mg/24 h, 
which were utilized for 12 h a day to avoid tolerance) and oral fluid intake (2.5 L of fluid per day). 
For each case enrolled in the ‘standard treatment’ group (Group A), one control, matched for 
maternal age (± 1 year), body mass index (BMI) (± 1 kg/m2), gestational age and severity of 
disease from a historical group of untreated FGR patients followed longitudinally, was included in 
the Group B. 
Approval of the local ethics committee was obtained based on a submitted protocol, and informed 
consent was obtained from all patients prior to enrolment. 
All patients were subjected to UltraSonic Cardiac Output Monitor (USCOM®, USCOM Ltd., 
Coffs Harbour, Australia) evaluation at the enrolment and after two weeks. 
 
Fetal ultrasound examination  
For the ultrasound examinations, a 3.5-MHz sector ultrasound transducer was used. Fetal biometry 
and estimated fetal weight were assessed according to local reference values. Doppler 
measurements were obtained from the UA, middle cerebral artery (MCA) and uterine artery. 
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Fetal biometry and Doppler measurements were obtained by a single specially trained examiner, 
using a Voluson E6 ®, GE Healthcare. 
 
 
Maternal hemodynamic assessment 
All haemodynamic measurements were obtained with USCOM®, a non-invasive Doppler 
ultrasonic technology for determination of haemodynamic variables. The USCOM® has been 
validated against invasive gold standards (7,8,9) USCOM® uses a non-imaging, continuous-wave 
Doppler transducer placed at the suprasternal notch to measure transaortic or transpulmonary 
blood flow. The acoustic beam directed in line with the valvular flow and a time–velocity spectral 
display is generated showing variations of the blood flow velocity with time. Once the optimal 
flow profile is obtained, the trace is frozen on the screen and the flow profiles automatically traced 
allowing the SV to be calculated as the product of the velocity-time integral and the cross-
sectional area (CSA) of the chosen valve. The CSA of the aortic valve is determined from the 
proprietary height-indexed regression equations. The CO is automatically calculated as the 
product of the heart rate (HR) and SV. SVR is calculated following the entry of systolic blood 
pressure (SBP) and the diastolic blood pressure (DBP) or the mean arterial pressure (MAP) (10). 
Only two trained operators were responsible for taking measurements. 
Statistical Analysis 
Values are expressed as mean ± SD. Clinical data were compared by means of independent 
samples Student’s t-test. Differences were considered as significant with p <0.05. 
 
Results 
Table 1 reports the demographic and pregnancy characteristics at the enrolment and the 
comparison of the outcome between the two groups. The two study populations were similar and 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
comparable at the enrolment in terms of parity, maternal age, height, weight and BMI; no 
significant differences were found in estimated fetal weight (EFW) at diagnosis of FGR, in fetal 
Doppler (UA pulsatility index [PI] and MCA PI), in gestational age at the enrolment and in the 
gestational age at delivery. There was a significant difference in terms of estimated fetal weight 
centile at the enrolment that was higher in group A (9.2±1.2 vs 6.5±1.7, p<00001). The uterine 
artery PI was significantly higher in the pregnancies in Group A (treated) than those in group B. 
The birth weight in grams and birth weight centile were significantly higher in Group A than 
Group B (2538.88±490 vs 2303±447 grams, p<0.05; 11±0.5 vs 3.66±1.5, p<0.05). 
In table 2 there is the comparison between the EFW at the enrolment and birth weight centile for 
each group evaluated longitudinally. In the group A there is a statistically significant increase of 
centile value after two weeks; on the contrary, group B shows a significant longitudinal reduction 
of the same. 
There were no statistically significant differences between the two groups in any of the 
cardiovascular parameters at the enrolment (Table 3). 
Table 4 shows the longitudinal evaluation of the hemodynamic parameters in the treated group 
(group A) and the untreated group (group B). As reported in table 3 and figures 1-3, in the treated 
group there were higher values of SV, SV index (SVI), CO and cardiac index (CI) at the second 
measurement (p<0.05). Moreover, the SVR values were significantly lower after two weeks of 
therapy (p<0.05). No significant differences were found after two weeks in the untreated group 
followed longitudinally, despite a slightly decrease of SVR values. 
 
Discussion 
Summary of findings 
The normal cardiovascular adaptation of the mother to pregnancy includes a number of 
haemodynamic changes such as the increase in CO and the SV associated with the reduction of 
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SVR and systemic arterial pressure values. These changes take place from the earliest weeks of 
pregnancy, reach their peak during the second trimester and then remain relatively constant until 
delivery. 
 
In our prospective cohort study we investigated the therapeutic effect of NO donors in pregnancies 
complicated by FGR and, in particular, their effect on maternal cardiovascular assessment. 
For this purpose, we compared maternal cardiovascular parameters in two groups of patients 
subjected to a different management of FGR: a treated group enrolled at the diagnosis of FGR and 
evaluated after two weeks therapy and a second group of untreated patients followed 
longitudinally. 
As shown in table 1, the two study populations were comparable in terms of maternal 
characteristics. Instead, in the treated group we noticed higher uterine artery Doppler PI values 
compared with Group B (untreated), suggesting these cases might present a worst impaired 
placentation process. 
Our results showed an overall improvement, after two weeks’ therapy, in cardiac function indices, 
particularly in CO, SV and SVR in the group treated with NO donors and oral fluids. On the 
contrary, the cardiovascular assessment in the untreated group, evaluated after two weeks, reflects 
a stable worst condition with SVR values persistently high. 
Another important aspect of NO donors treatment is the increase in heart rate, which is typically 
lower in pregnancy complicated by FGR. In our study there was a slight increase in HR two weeks 
after therapy although it does not reach statistical significance. The enrolment of a second 
historical control group of untreated FGR patients allows us to demonstrate that the finding of 
elevated SVR values in these kind of patients in not only an accidental result but might be 
replicated in different clinical setting, investigated with the same method. The availability of a 
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control-untreated group permitted to testify that the therapy regimen adopted gives a significant 
reduction of SVR in the treated group. 
Although it wasn’t our first endpoint and we especially focused on cardiovascular effect of NO 
donors therapy, our data showed a statistically significant improvement of fetal growth. The 
estimated fetal weight percentile for the treated group at study enrolment was on the 9th 
percentile, higher than the control group (6th percentile). Even if the treated group “starting point” 
could be considered better, the analysis of birthweight centile showed a significant difference (11th 
vs third centile, respectively) demonstrating that therapy may be also effectiveness in improving 
fetal growth. 
 
Comparison with existing literature 
Several studies in literature have shown that abnormalities of these adaptive mechanisms in the 
placental vascular bed are related to several disorders of pregnancy, in particular, pregnancy-
induced hypertension (PIH) and FGR. Transdermal GTN patches have been widely studied for 
both prevention and management of preeclampsia and related disorders (11) and it seems an 
attractive tool in improving uterine and umbilical blood flow. Moreover, it protects 
syncytiotrophoblast from apoptosis, lipid peroxidation, and superoxide formation following 
hypoxia-reperfusion insults. 
A prospective case-control study conducted by Melchiorre demonstrated that growth-restricted 
pregnancies are characterized by a lower CI and higher SVRI than expected for gestation (12). As 
regard therapy with NO donors, several studies in the past have demonstrated their effectiveness in 
improving outcome of FGR pregnancies. Some authors have, also, demonstrated the reappearance 
of end-diastolic flow in the UA associated with an improvement in fetal outcome during NO 
donors treatment (13,14). 
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Research and clinical implications 
On the basis of our results, we can speculate the beneficial effect of NO donors and fluid 
management. The most interesting aspect is the double and synergistic action on both afterload 
and preload of our therapy. In fact, oral fluid management induces an increase in preload, that is 
typically reduced in pregnancies complicated by FGR. At the same time, NO donors 
administration reduces afterload acting on SVR.  
We can speculate that CO and SVR could therefore represent a good method to evaluate the 
efficacy of our combined therapy, confirming that improvement in maternal cardiovascular 
function could potentially have a positive effect on fetal growth. On the basis of the results of our 
study, the maternal "cardiac pump" would play a central and decisive role in the evolution of the 
pregnancy and the study of maternal cardiovascular function could be useful in understanding the 
maternal response to impaired placentation, and therefore, improving our prognostic ability. 
 
Strenght and weakness 
Most of the current existing studies in literature investigated both the maternal hemodynamic 
changes and effectiveness of therapy using transthoracic echocardiography. This is a widely 
accepted methodology for CO estimation in pregnancy, considered safe and acceptable due to its 
non-invasive nature.  However, this method requires both costly equipment and clinical expertise, 
thereby limiting availability.  In the current study we use a non invasive method, the USCOM® 
system, simple to use with measurements obtained in minutes, with minimal training required to 
achieve operative proficiency.  
The accuracy of the system has been proven in a number of studies, when compared with other 
methods and in various clinical applications. USCOM® comparisons with flow probes in computer 
controlled flow simulator demonstrated a variation of less than 5% and, as shown in a previous 
study (15), the mean difference of CI was 0.16 ± 0.59 l/min/m, and the correlation coefficient was 
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0.87. Several studies demonstrated a good reproducibility of USCOM in pregnant women. A study 
conducted in 2016 by Khalil et al demonstrate that USCOM® has a good agreement with 
echocardiography in the third trimester. The level of agreement between USCOM® and 
echocardiography in the third trimester meets the recommended level of clinical acceptability. The 
intra-class correlation coefficient for CO estimation was 0.969 (95% CI 0.953-0.980). The 
interobserver reproducibility varied from 0.899 (95% CI 0.790-0.952) in the first trimester, 0.969 
(95% CI 0.88-0.992) in the second trimester, and 0.965 (95% CI 0.185- 0.990) in the third 
trimester. The intra-class correlation coefficient for CO was 0.896 (95% CI 0.812-0.944) (16). 
A limitation of this study could be the small sample size and the observational nature of the study. 
However, despite the small sample size, it was adequate to demonstrate the effectiveness of 
therapy.  
 
Conclusions 
In conclusion, despite the observation nature of data and several limits of the study, our results 
might open new perspectives in the treatment of fetal growth restriction, focusing on main 
maternal cardiovascular anomalies. This view would place the focus of the evaluation of TVR and 
CO, becoming a central target for the therapies.  
Although these initial results are encouraging, they must be confirmed in a properly controlled 
RCT, with an adequate study population. 
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Table 1. Characteristics of the study population 
 
Group A (treated) Group B (untreated) p value A-B
(n=26) (n=26)
Nulliparous 18 (69.23) 20 (76.92) 0.39
Maternal age (years) 32.27±4.9 33.33±3.8 0.38
Maternal height (metres) 1.62±0.1 1.58±0.07 0.10
Maternal weight (kilograms) 65.13±15.8 60.16±9.6 0.17
Maternal BMI (kg/m2) 24.8±1.8 23.82±2.14 0.08
Estimated fetal weight in grams at recruitment 1437±465.4 1405±291.39 0.76
Estimated fetal weight centile at recruiment 9.2±1.2 6.5±1.7 p<0.0001
Umbilical artery pulsatility index(PI) 0.99±0.3 1±0.2 0.88
Middle cerebral artery PI 1.85±0.3 1.83±0.41 0.84
Uterine artery PI 1.2±0.2 0.90±0.16 p<0.05
Gestational age at enrollement 30.77±0.33 30.33±1.21 0.07
Birth weight (grams) 2538.88±490 2303±447 p<0.05
Birth weight centile 11±0.5 3.66±1.5 p<0.05
Gestational age at delivery 37.19±2.5 37 ±2.6 0.78  
 
 
 
Table 2. Difference in percentile pre and post in each group longitudinally 
 
EFW centile at recruiment Birth weight centile p value
Group A (treated) 9.2±1.2 11±0.5 p<0,01
Group B (untreated) 6.5±1.7 3.66±1.5 p<0,01  
 
 
 
 
Table 3. Maternal hemodynamic parameters at enrolment 
 
Group A (treated) Group B (untreated) p value A-B
Heart Rate (HR) 78.33±12.7 77.83±11.8 0.88
Ejection Time % (ET%) 40.95±5.7 41.48±6.97 0.76
Stroke Volume (SV) 73.76±11.5 71.9±17.11 0.64
Stroke Volume Index (SVI) 42.98±7.9 42.8±0.6 0.9
Cardiac Output (CO) 5.81±1.1 5.48±0.9 0.24
Cardiac Index (CI) 3.46±0.7 3.29±0.37 0.27
Sistolic Arterial Pressure (SAP) 112.58±13.3 115±12.24 0.49
Diastolic Arterial Pressure (DAP) 71.92±10.8 73.66±7.73 0.50
Mean Arterial Pressure (MAP) 84.15±11.3 87.16±8.7 0.28
Systemic Vascular Resistence (SVR) 1215.39±230.2 1314.83±219 0.11
SVR Index (SVRI) 2100.51±447.5 2140±257.40 0.69  
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Table 4. Maternal hemodynamic in group A (treated) before and after therapy and in group B 
(untreated) 
 
Group A (before therapy) Group A (after therapy) Δ (%) p value Group B untreated Group B untreated (after 2 wks) Δ (%) p value
Heart Rate (HR) 78.33±12.7 80.57±10.48 2.86 0.48 77.83±11,8 79.33±8.53 1.89 0.60
Ejection Time % (ET%) 40.95±5.7 42.86±6.50 4.66 0.25 4.,48±6.97 44.33±7.11 6.87 0.15
Stroke Volume (SV) 73.76±11.5 83.11±16.78 12.68 p<0.05 71.9±17.11 70.96±16.4 -1.31 0.84
Stroke Volume Index (SVI) 42.98±7.9 48.13±10.22 11.98 p<0.05 42.8±0.6 42.5±0.74 -0.70 0.11
Cardiac Output (CO) 5.81±1.1 6.60±1.03 13.60 p<0.05 5.48±0.9 5.74±0.72 4.74 0.25
Cardiac Index (CI) 3.46±0.7 3.88±0.66 12.14 p<0.05 3.29±0.37 3.6±0.98 9.42 0.13
Sistolic Arterial Pressure (SAP) 112.58±13.3 108.81±12.98 -3.35 0.30 115±12.24 109±14.16 -5.22 0.10
Diastolic Arterial Pressure (DAP) 71.92±10.8 69.42±11.12 -3.48 0.41 73.66±7.73 69.83±10.34 -5.20 0.13
Mean Arterial Pressure (MAP) 84.15±11.3 82.77±11.08 -1.64 0.65 87.16±8.7 82.83±10.8 -4.97 0.11
Systemic Vascular Resistence (SVR) 1215.39±230.2 1022.43±195.35 -15.88 p<0.05 1314.83±219 1290±135 -1.89 0.62
SVR Index (SVRI) 2100.51±447.5 1786.04±387.56 -14.97 p<0.05 2140±257.40 2112±249.28 -1.31 0.69  
 
 
 
 
 
 
 
 
 
Figure Legends: 
 
Fig. 1:  SV variation after two weeks therapy 
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Fig. 2:  CO variation after two weeks therapy 
 
 
Fig. 3: SVR reduction after two weeks therapy 
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Fig 4: Strobe flowchart 
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